A "Kit" for increasing insulin production

18 July 2012

The critical role of a receptor called c-Kit in the development and function of insulin-producing beta cells, has been identified by scientists from Western University in London, Canada, and the Children's Health Research Institute, an Institute within the Lawson Health Research Institute, making it an exciting therapeutic target for the management of diabetes.

The research, led by Rennian Wang, demonstrated that over-expression of c-Kit not only leads to increased insulin production but also counteracts the early diabetic effects of a high-fat diet. The paper and an accompanying commentary, are published in the August issue of Diabetologia, and featured in the Research Highlights in Nature Reviews Endocrinology.

Diabetes is one of the most common metabolic diseases affecting over 25 million Americans and 2 million Canadians. It is associated with a multitude of complications leading to considerable morbidity and a major medical as well as financial burden on society.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical